Cassava Sciences (NASDAQ:SAVA) traded higher in the premarket on Tuesday after the Alzheimer’s drug developer received its only buy rating on Wall Street as H.C. Wainwright upgraded the stock, citing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results